FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135490889> ?p ?o ?g. }

• W2135490889 abstract "Background Neuroblastoma is a rare malignant disease and mainly affects infants and very young children. The tumours mainly develop in the adrenal medullary tissue, with an abdominal mass as the most common presentation. About 50% of patients have metastatic disease at diagnosis. The high‐risk group is characterised by metastasis and other features that increase the risk of an adverse outcome. High‐risk patients have a five‐year event‐free survival of less than 50%. Retinoic acid has been shown to inhibit growth of human neuroblastoma cells and has been considered as a potential candidate for improving the outcome of patients with high‐risk neuroblastoma. This review is an update of a previously published Cochrane Review. Objectives To evaluate the efficacy and safety of additional retinoic acid as part of a postconsolidation therapy after high‐dose chemotherapy (HDCT) followed by autologous haematopoietic stem cell transplantation (HSCT), compared to placebo retinoic acid or to no additional retinoic acid in people with high‐risk neuroblastoma (as defined by the International Neuroblastoma Risk Group (INRG) classification system). Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (2016, Issue 11), MEDLINE in PubMed (1946 to 24 November 2016), and Embase in Ovid (1947 to 24 November 2016). Further searches included trial registries (on 22 December 2016), conference proceedings (on 23 March 2017) and reference lists of recent reviews and relevant studies. We did not apply limits by publication year or languages. Selection criteria Randomised controlled trials (RCTs) evaluating additional retinoic acid after HDCT followed by HSCT for people with high‐risk neuroblastoma compared to placebo retinoic acid or to no additional retinoic acid. Primary outcomes were overall survival and treatment‐related mortality. Secondary outcomes were progression‐free survival, event‐free survival, early toxicity, late toxicity, and health‐related quality of life. Data collection and analysis We used standard methodological procedures expected by Cochrane. Main results The update search did not identify any additional studies. We identified one RCT that included people with high‐risk neuroblastoma who received HDCT followed by autologous HSCT (N = 98) after a first random allocation and who received retinoic acid (13‐cis‐retinoic acid; N = 50) or no further therapy (N = 48) after a second random allocation. These 98 participants had no progressive disease after HDCT followed by autologous HSCT. There was no clear evidence of difference between the treatment groups either in overall survival (hazard ratio (HR) 0.87, 95% confidence interval (CI) 0.46 to 1.63; one trial; P = 0.66) or in event‐free survival (HR 0.86, 95% CI 0.50 to 1.49; one trial; P = 0.59). We calculated the HR values using the complete follow‐up period of the trial. The study also reported overall survival estimates at a fixed point in time. At the time point of five years, the survival estimate was reported to be 59% for the retinoic acid group and 41% for the no‐further‐therapy group (P value not reported). We did not identify results for treatment‐related mortality, progression‐free survival, early or late toxicity, or health‐related quality of life. We could not rule out the possible presence of selection bias, performance bias, attrition bias, and other bias. We judged the evidence to be of low quality for overall survival and event‐free survival, downgraded because of study limitations and imprecision. Authors' conclusions We identified one RCT that evaluated additional retinoic acid as part of a postconsolidation therapy after HDCT followed by autologous HSCT versus no further therapy in people with high‐risk neuroblastoma. There was no clear evidence of a difference in overall survival and event‐free survival between the treatment alternatives. This could be the result of low power. Information on other outcomes was not available. This trial was performed in the 1990s, since when many changes in treatment and risk classification have occurred. Based on the currently available evidence, we are therefore uncertain about the effects of retinoic acid in people with high‐risk neuroblastoma. More research is needed for a definitive conclusion." @default.
• W2135490889 created "2016-06-24" @default.
• W2135490889 creator A5029704913 @default.
• W2135490889 creator A5044985959 @default.
• W2135490889 creator A5046328006 @default.
• W2135490889 creator A5061652360 @default.
• W2135490889 date "2017-08-25" @default.
• W2135490889 modified "2023-09-26" @default.
• W2135490889 title "Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation" @default.
• W2135490889 cites W1511277433 @default.
• W2135490889 cites W1522370347 @default.
• W2135490889 cites W1538160646 @default.
• W2135490889 cites W1801634746 @default.
• W2135490889 cites W1826533514 @default.
• W2135490889 cites W1899939340 @default.
• W2135490889 cites W1917242018 @default.
• W2135490889 cites W1926885922 @default.
• W2135490889 cites W1932572494 @default.
• W2135490889 cites W1945302280 @default.
• W2135490889 cites W1948602427 @default.
• W2135490889 cites W1960710326 @default.
• W2135490889 cites W1965114854 @default.
• W2135490889 cites W1966846121 @default.
• W2135490889 cites W1968910032 @default.
• W2135490889 cites W1971603972 @default.
• W2135490889 cites W1975406464 @default.
• W2135490889 cites W1976029914 @default.
• W2135490889 cites W1976935354 @default.
• W2135490889 cites W1978151475 @default.
• W2135490889 cites W1979904309 @default.
• W2135490889 cites W1993910627 @default.
• W2135490889 cites W1996375905 @default.
• W2135490889 cites W2001699818 @default.
• W2135490889 cites W2005445277 @default.
• W2135490889 cites W2010269181 @default.
• W2135490889 cites W2012219845 @default.
• W2135490889 cites W2014041765 @default.
• W2135490889 cites W2018183462 @default.
• W2135490889 cites W2018309349 @default.
• W2135490889 cites W2026959715 @default.
• W2135490889 cites W2027509561 @default.
• W2135490889 cites W2027884825 @default.
• W2135490889 cites W2029590939 @default.
• W2135490889 cites W2035644332 @default.
• W2135490889 cites W2037952528 @default.
• W2135490889 cites W2038283680 @default.
• W2135490889 cites W2041763055 @default.
• W2135490889 cites W2046335521 @default.
• W2135490889 cites W2052301310 @default.
• W2135490889 cites W2054524692 @default.
• W2135490889 cites W2060324001 @default.
• W2135490889 cites W2074070461 @default.
• W2135490889 cites W2075642745 @default.
• W2135490889 cites W2077242620 @default.
• W2135490889 cites W2080526137 @default.
• W2135490889 cites W2083384978 @default.
• W2135490889 cites W2083509470 @default.
• W2135490889 cites W2087141010 @default.
• W2135490889 cites W2088095316 @default.
• W2135490889 cites W2088130748 @default.
• W2135490889 cites W2088164154 @default.
• W2135490889 cites W2089349742 @default.
• W2135490889 cites W2090116283 @default.
• W2135490889 cites W2092600315 @default.
• W2135490889 cites W2096398040 @default.
• W2135490889 cites W2101546733 @default.
• W2135490889 cites W2102118318 @default.
• W2135490889 cites W2106568960 @default.
• W2135490889 cites W2107328434 @default.
• W2135490889 cites W2108217633 @default.
• W2135490889 cites W2111733282 @default.
• W2135490889 cites W2113179687 @default.
• W2135490889 cites W2118171008 @default.
• W2135490889 cites W2119755334 @default.
• W2135490889 cites W2121712825 @default.
• W2135490889 cites W2125418673 @default.
• W2135490889 cites W2125435699 @default.
• W2135490889 cites W2130465135 @default.
• W2135490889 cites W2132322911 @default.
• W2135490889 cites W2132855064 @default.
• W2135490889 cites W2132914428 @default.
• W2135490889 cites W2136462971 @default.
• W2135490889 cites W2137648684 @default.
• W2135490889 cites W2139201146 @default.
• W2135490889 cites W2140839532 @default.
• W2135490889 cites W2143824353 @default.
• W2135490889 cites W2144152847 @default.
• W2135490889 cites W2144440669 @default.
• W2135490889 cites W2147800896 @default.
• W2135490889 cites W2148888804 @default.
• W2135490889 cites W2152420890 @default.
• W2135490889 cites W2157272402 @default.
• W2135490889 cites W2158310959 @default.
• W2135490889 cites W2164097016 @default.
• W2135490889 cites W2176479197 @default.
• W2135490889 cites W2185464770 @default.
• W2135490889 cites W2261192711 @default.
• W2135490889 cites W2280912529 @default.
• W2135490889 cites W2312664798 @default.
• W2135490889 cites W2313741869 @default.

• next